Both Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) and Osmotica Pharmaceuticals plc (NASDAQ:OSMT) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ritter Pharmaceuticals Inc.	N/A	0.00	19.41M	-3.08	0.00
Osmotica Pharmaceuticals plc	263.70M	0.73	109.40M	-0.13	0.00

Table 1 shows the gross revenue, earnings per share and valuation for Ritter Pharmaceuticals Inc. and Osmotica Pharmaceuticals plc.

Profitability

Table 2 shows us Ritter Pharmaceuticals Inc. and Osmotica Pharmaceuticals plc’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Ritter Pharmaceuticals Inc.	0.00%	-135%	-86.8%
Osmotica Pharmaceuticals plc	-41.49%	0%	0%

Liquidity

The current Quick Ratio of Ritter Pharmaceuticals Inc. is 5.1 while its Current Ratio is 5.1. Meanwhile, Osmotica Pharmaceuticals plc has a Current Ratio of 1.3 while its Quick Ratio is 1.1. Ritter Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Osmotica Pharmaceuticals plc.

Institutional & Insider Ownership

Ritter Pharmaceuticals Inc. and Osmotica Pharmaceuticals plc has shares held by institutional investors as follows: 24.3% and 51.5%. 13.5% are Ritter Pharmaceuticals Inc.’s share held by insiders. Competitively, insiders own roughly 42.7% of Osmotica Pharmaceuticals plc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Ritter Pharmaceuticals Inc.	5.89%	10.35%	-16.1%	-68.84%	-73.95%	8.53%
Osmotica Pharmaceuticals plc	0.84%	-8.42%	5.43%	0%	0%	-7.35%

For the past year Ritter Pharmaceuticals Inc. has 8.53% stronger performance while Osmotica Pharmaceuticals plc has -7.35% weaker performance.

Summary

Osmotica Pharmaceuticals plc beats on 5 of the 9 factors Ritter Pharmaceuticals Inc.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. The companyÂ’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. It is also exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing various conditions, including gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.